Dwight,
I like both companies, and both have potential to skyrocket.
I think the delay in the NDA for Cytolex is disheartening, but not a "partial fizzle". If the NDA goes in and the FDA passes it, then we have our first magainin drug. It isn't as powerful as what they have in their arsenal now, but that is what they had 8 years ago...With this success, they can find other applications for Cytolex, and the other peptide drugs their developing. then, of course, they have the squalamine and asthma drugs in the pipeline.
TCLN also has great science, but had serious problems in financing - which, in turn, caused major rifts within the company, and with shareholders. The price dropped dramatically. The fact is, TCLN may very soon demonstrate effective treatment for gliomas as well as other tumors...A worthwhile investment IMO.
Good Luck,
Shep |
